medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2017, Number 4

<< Back

Rev Mex Urol 2017; 77 (4)

Glutathione S-transferase T1 and M1 gene polymorphisms as prognostic factors for bladder cancer: limited evidence and still unresolved inconsistencies

Meng XY, Shi MJ

Language: Spanish
References: 10
Page: 336-338
PDF size: 254.20 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Yu C, Hequn C, Longfei L, et al. GSTM1 and GSTT1 polymorphisms are associated with increased bladder cancer risk: Evidence from updated meta-analysis. Oncotarget. 2017;8(2):3246-58.

  2. Kim EJ, Jeong P, Quan C, et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology. 2005;65(1):70-5.

  3. Norskov MS, Frikke-Schmidt R, Bojesen SE, et al. Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population. Pharmacogenomics J. 2011;11(4):292-9.

  4. Ha YS, Yan C, Lym MS, et al. GSTT1 as a prognosticator for recurrence and progression in patients with non-muscleinvasive bladder cancer. Dis Markers. 2010;29(2):81-7.

  5. Ha YS, Yan C, Jeong P, et al. GSTM1 tissue genotype as a recurrence predictor in non-muscle invasive bladder cancer. J Korean Med Sci. 2011;26(2):231-6.

  6. Roth E, Selinski S, Schikowsky C, et al. Bladder cancer survival in a former industrial area in Saxony-Anhalt, Germany. J Toxicol Environ Health A. 2012;75(19-20):1216-25.

  7. Djukic TI, Savic-Radojevic AR, Pekmezovic TD, et al. Glutathione S-transferase T1, O1 and O2 polymorphisms are associated with survival in muscle invasive bladder cancer patients. PloS One. 2013;8(9):e74724.

  8. Kang HW, Song PH, Ha YS, et al. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility and outcomes in muscle invasive bladder cancer patients. Eur J Cancer. 2013;49(14):3010-9.

  9. Kang HW, Tchey DU, Yan C, et al. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer. Urol Oncol. 2014;32(4):458-65.

  10. Lacombe L, Fradet V, Levesque E, et al. Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. Cancer Prev Res (Phila). 2016;9(2):189-95.




2020     |     www.medigraphic.com